Annuncio pubblicitario
Italia markets close in 8 hours 12 minutes

  • FTSE MIB

    34.184,65
    +197,75 (+0,58%)
     

  • Dow Jones

    38.852,27
    +176,59 (+0,46%)
     

  • Nasdaq

    16.349,25
    +192,92 (+1,19%)
     

  • Nikkei 225

    38.835,10
    +599,03 (+1,57%)
     

  • Petrolio

    78,47
    -0,01 (-0,01%)
     

  • Bitcoin EUR

    59.124,64
    -563,48 (-0,94%)
     

  • CMC Crypto 200

    1.367,60
    +2,47 (+0,18%)
     

  • Oro

    2.327,60
    -3,60 (-0,15%)
     

  • EUR/USD

    1,0765
    -0,0008 (-0,08%)
     

  • S&P 500

    5.180,74
    +52,95 (+1,03%)
     

  • HANG SENG

    18.482,30
    -96,00 (-0,52%)
     

  • Euro Stoxx 50

    4.981,42
    +24,46 (+0,49%)
     

  • EUR/GBP

    0,8582
    +0,0010 (+0,12%)
     

  • EUR/CHF

    0,9756
    -0,0000 (-0,00%)
     

  • EUR/CAD

    1,4729
    +0,0014 (+0,09%)
     

Vericel to Present at the Morgan Stanley Global Healthcare Conference

Vericel Corporation
·1 minuto per la lettura
Vericel Corporation
Vericel Corporation

CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference at 7:30 a.m. ET on Tuesday, September 12, 2023.

A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.

About Vericel Corporation

Vericel is a leader in advanced therapies for sports medicine and severe burn care. The Company manufactures and markets two cell therapy products and one specialty biologic product in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel also holds an exclusive license for North American rights to NexoBrid® (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adults with deep partial-thickness and/or full-thickness burns. For more information, please visit www.vcel.com.

ANNUNCIO PUBBLICITARIO

Epicel® and MACI® are registered trademarks of Vericel Corporation. NexoBrid® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2023 Vericel Corporation. All rights reserved.

Investor Contacts:
Eric Burns
ir@vcel.com
+1 (734) 418-4411

Media Contact:
Julie Downs
media@vcel.com